ProKidney Corp.
Jennifer Gilbert currently serves as a Quality Assurance Specialist II at ProKidney Corp. since October 2023, following a role as Quality Assurance Specialist at Catalent Pharma Solutions and Mayne Pharma. Prior experience includes a position as Aerosol Supervisor at FAREVA and a dual-role experience at Beiersdorf, where responsibilities spanned Engineering Technician/Supervisor and Production Supervisor. Jennifer's career initiated at Bayer as a Manufacturing Supervisor and extended to a managerial position at Merck as Manager of Operations. Early career highlights include roles as Inventory Production Specialist and Operator at Schering Plough. Jennifer holds a Bachelor of Science in Psychology from The University of Tennessee at Chattanooga and an Associate of Science in Psychology from Cleveland State Community College.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.